Our novel class of nocions™ are small molecule charged sodium channel blockers (CSCBs) designed to deliver a new treatment option for millions of people living with debilitating chronic conditions arising from sensory neuron hypersensitivity including cough, pain, itch, and neurogenic inflammation. Our lead clinical program is taplucainium inhalation powder, a first-in-class locally delivered small molecule nocion in Phase 2b clinical development for refractory and unexplained chronic cough (rCC/uCC), with the potential for sub-acute and other cough indications.
We have a rich portfolio of nocions and have generated initial proof of concept across multiple indications. For each indication, we have developed unique molecules with distinct formulations and a strong IP portfolio.
Refractory/unexplained chronic cough (rCC/uCC; ASPIRE study topline expected Q3 2026)
Sub-acute/other (Acute cough, post-viral cough, asthma/COPD cough, idiopathic pulmonary fibrosis (IPF) cough, and interstitial lung disease (ILD) cough.)
Dermatological (atopic dermatitis, psoriasis, prurigo nodularis, pruritus)
Pain (neuralgia/neuropathic pain, rheumatoid and osteoarthritis, post operative pain)
Upper/lower GI (IBD/IBS, anal/rectal itch and pain, oral/esophageal/GI pain)
Women’s health (vulvodynia, genital itch and pain, interstitial cystitis, endometriosis)
Oncology (IO therapy for various cancers, cancer itch and pain, oral mucositis)
Ocular (dry eye syndrome, ocular pain, allergic conjunctivitis)
